MD4890B1 - Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia - Google Patents

Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia Download PDF

Info

Publication number
MD4890B1
MD4890B1 MDA20210028A MD20210028A MD4890B1 MD 4890 B1 MD4890 B1 MD 4890B1 MD A20210028 A MDA20210028 A MD A20210028A MD 20210028 A MD20210028 A MD 20210028A MD 4890 B1 MD4890 B1 MD 4890B1
Authority
MD
Moldova
Prior art keywords
composition
preparation
combination vaccine
reduced dose
inactivated poliovirus
Prior art date
Application number
MDA20210028A
Other languages
English (en)
Russian (ru)
Other versions
MD20210028A2 (ro
MD4890C1 (ro
Inventor
Индер Джит ШАРМА
Кумар РАКЕШ
Джаганатан Сембураккианнан КИЛВАНИ
Манохар ДОДДАПАНЕНИ
Анил Вьянкатрао ШИТОЛЕ
Original Assignee
Serum Institute Of India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Private Ltd filed Critical Serum Institute Of India Private Ltd
Publication of MD20210028A2 publication Critical patent/MD20210028A2/ro
Publication of MD4890B1 publication Critical patent/MD4890B1/ro
Publication of MD4890C1 publication Critical patent/MD4890C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la o compoziţie imunogenică complet lichidă, care include o combinaţie de antigeni/imunogeni. Compoziţia imunogenică include o cantitate optimă de antigeni/imunogeni pentru asigurarea protecţiei împotriva unui şir de boli. Compoziţia manifestă imunogenicitate şi stabilitate îmbunătăţite. De asemenea, prezenta invenţie se referă la un procedeu de preparare a compoziţiei de vaccin.
MDA20210028A 2018-10-12 2019-10-04 Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia MD4890C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821038850 2018-10-12
PCT/IN2019/050737 WO2020075184A1 (en) 2018-10-12 2019-10-04 Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same

Publications (3)

Publication Number Publication Date
MD20210028A2 MD20210028A2 (ro) 2021-11-30
MD4890B1 true MD4890B1 (ro) 2024-04-30
MD4890C1 MD4890C1 (ro) 2024-11-30

Family

ID=68542707

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20210028A MD4890C1 (ro) 2018-10-12 2019-10-04 Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia

Country Status (22)

Country Link
US (1) US12090195B2 (ro)
EP (1) EP3863665A1 (ro)
JP (1) JP7478144B2 (ro)
KR (1) KR102822878B1 (ro)
CN (1) CN113164577B (ro)
AR (1) AR116631A1 (ro)
AU (1) AU2019359564B2 (ro)
BR (1) BR112021006707A2 (ro)
CA (1) CA3115803A1 (ro)
CO (1) CO2021004556A2 (ro)
EA (1) EA202190778A1 (ro)
GE (2) GEP20247684B (ro)
JO (1) JOP20190242B1 (ro)
MD (1) MD4890C1 (ro)
MX (1) MX2021004233A (ro)
PE (1) PE20211648A1 (ro)
PH (1) PH12021550812A1 (ro)
SG (1) SG11202103622SA (ro)
TW (1) TW202034948A (ro)
UY (1) UY38412A (ro)
WO (1) WO2020075184A1 (ro)
ZA (1) ZA202103154B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN112316126B (zh) * 2020-10-29 2021-08-13 武汉生物制品研究所有限责任公司 一种氢氧化铝佐剂吸附百日咳菌毛(Fim)抗原制品的制备方法
CN116355083B (zh) * 2023-05-30 2023-09-08 国药中生生物技术研究院有限公司 特异性结合脊髓灰质炎病毒i型抗原的抗体
WO2025252927A1 (en) * 2024-06-07 2025-12-11 The Provost, Fellows, Foundation Scholars & The Other Members Of Board, Of The College Of The Holy & Undivided Trinity Of Queen Elizabeth Near Dublin Vaccine compositions and methods and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69018990T2 (de) 1989-07-14 1995-12-14 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
FI945483A7 (fi) 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
WO1998034594A1 (en) 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
CA2303105A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
US20040258700A1 (en) * 2003-06-23 2004-12-23 Frimann Tine Holland Vaccine formulation with a preservative
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) 2006-08-15 2006-09-27 Novartis Ag Processes
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
CN101835797A (zh) * 2007-11-23 2010-09-15 上海泽润生物科技有限公司 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
EP3459562B1 (en) 2011-01-05 2024-03-20 Bharat Biotech International Limited A combination heptavalent vaccine
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
EA037283B1 (ru) 2015-09-16 2021-03-04 ЭлДжи КЕМ, ЛТД. Комбинированная вакцинная композиция для многократного дозирования
SG11201900365WA (en) 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
GEP20227386B (en) * 2017-07-18 2022-06-10 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.

Also Published As

Publication number Publication date
GEAP202415627A (en) 2024-05-13
MD20210028A2 (ro) 2021-11-30
UY38412A (es) 2020-04-30
SG11202103622SA (en) 2021-05-28
WO2020075184A1 (en) 2020-04-16
KR102822878B1 (ko) 2025-06-20
JOP20190242B1 (ar) 2025-10-01
GEP20247684B (en) 2024-10-28
ZA202103154B (en) 2022-03-30
PH12021550812A1 (en) 2021-11-08
AU2019359564B2 (en) 2026-02-05
JP7478144B2 (ja) 2024-05-02
CN113164577A (zh) 2021-07-23
JOP20190242A1 (ar) 2020-04-12
TW202034948A (zh) 2020-10-01
AR116631A1 (es) 2021-05-26
MD4890C1 (ro) 2024-11-30
BR112021006707A2 (pt) 2021-07-27
US20210346483A1 (en) 2021-11-11
MX2021004233A (es) 2021-08-16
EP3863665A1 (en) 2021-08-18
PE20211648A1 (es) 2021-08-24
CN113164577B (zh) 2024-06-18
CA3115803A1 (en) 2020-04-16
EA202190778A1 (ru) 2021-08-05
JP2022502469A (ja) 2022-01-11
CO2021004556A2 (es) 2021-04-30
AU2019359564A1 (en) 2021-06-03
US12090195B2 (en) 2024-09-17
KR20210091158A (ko) 2021-07-21

Similar Documents

Publication Publication Date Title
MD4890B1 (ro) Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
MX364689B (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
CL2019000704A1 (es) Vectores de adenovirus canino.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BR112018074483A2 (pt) proteínas f do rsv pré-fusão estabilizadas
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
Rathore et al. Immunogen design for HIV-1 and influenza
EA201690115A1 (ru) Комбинированные иммуногенные композиции
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
MX363149B (es) Vacunas de nucleoproteina de la influenza.
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
MX2017000154A (es) Sistema de rinovacunacion de la vacuna contra la influenza.
MA42317B2 (fr) Composition de vaccin combinée pour administration multiple
WO2019191586A3 (en) Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
EP3069730A3 (en) Soluble hiv-1 envelope glycoprotein trimers
EA201270794A8 (ru) Маркерная вакцина против классической чумы свиней
MX2017016858A (es) Composiciones inmunogenicas.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
WO2020071869A8 (ko) 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도

Legal Events

Date Code Title Description
FG4A Patent for invention issued